| 01/13 | Wedbush Raises Price Target for Ascendis Pharma A/S to $189 From $186 on EU Approval fo.. | MT |
| 01/13 | Ascendis Pharma's Growth Hormone Drug TransCon hGH Gets EU Approval | MT |
| 01/13 | Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Gr.. | AQ |
| 01/13 | Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Gro.. | CI |
| 01/13 | Wedbush Cuts Ascendis Pharma's PT to $186 From $191 on Skytrofa Contraindication for PW.. | MT |
| 01/11 | European ADRs Nudge Lower in Tuesday Trading | MT |
| 01/10 | Ascendis Pharma A/S Provides Update on Vision 3x3 Strategic Roadmap at 40th Annual J.P... | AQ |
| 01/06 | European ADRs Move Higher in Thursday Trading | MT |
| 01/06 | Cowen Starts Ascendis Pharma at Market Perform With $136 Price Target | MT |
| 01/05 | European ADRs Move Higher in Wednesday Trading | MT |
| 01/04 | Ascendis Pharma A/S to Participate in 40th Annual J.P. Morgan Healthcare Conference | GL |
| 2021 | Ascendis Pharma A/S Virtual R&D Program Update Highlights Continued Development Across .. | AQ |
| 2021 | Ascendis Pharma A/S to Provide an Update on Two of Its Investigational Endocrinology Ra.. | CI |
| 2021 | Wells Fargo Starts Ascendis Pharma at Overweight With $176 Price Target | MT |
| 2021 | Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14 | GL |
| 2021 | European ADRs Move Sharply Lower in Friday Trading | MT |
| 2021 | Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forwar.. | GL |
| 2021 | Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward.. | CI |
| 2021 | Ascendis Pharma A/S Elects Rafa?le Tordjman as A Class II Director | CI |
| 2021 | Ascendis Pharma A/S to Participate in the Evercore ISI 4th Annual HealthCONx Conference | AQ |
| 2021 | European ADRs Mixed in Tuesday Morning Trading | MT |
| 2021 | SVB Leerink Adjusts Ascendis Pharma's Price Target to $190 from $182, Keeps Outperform .. | MT |
| 2021 | Ascendis Pharma A/S - Share Repurchase Program Update | AQ |
| 2021 | Ascendis Pharma Says EMA Panel Issues Positive Opinion Backing Approval of Growth Hormo.. | MT |
| 2021 | Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon™ hGH for Patients.. | GL |
| 2021 | Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon? hGH for Patients with .. | CI |
| 2021 | Credit Suisse Lowers Ascendis Pharma's PT to $179 from $185, Updates Model with Q3 Actu.. | MT |
| 2021 | Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results - Form 6-K | PU |
| 2021 | ASCENDIS PHARMA A/S INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEME.. | PU |
| 2021 | Ascendis Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ende.. | CI |
| 2021 | Ascendis Pharma's Q3 Loss Shrinks Even as Revenue Slips | MT |
| 2021 | Tranche Update on Ascendis Pharma A/S's Equity Buyback Plan announced on September 29, .. | CI |
| 2021 | Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results | AQ |
| 2021 | Ascendis Pharma A/S's Equity Buyback announced on September 29, 2021, has expired with .. | CI |
| 2021 | Ascendis Pharma A/S Presents New Non-Clinical Data for TransCon™ TLR7/8 Agonist O.. | AQ |
| 2021 | Ascendis Pharma A/S Presents New Non-Clinical Data?for TransCon TLR7/8 Agonist Oncology.. | CI |
| 2021 | Ascendis Pharma A/S - Share Repurchase Program Update | AQ |
| 2021 | Ascendis Pharma A/S Announces Third Quarter 2021 Financial Results and Business Update .. | AQ |
| 2021 | Trump's real-estate empire pays the price for poisonous politics | RE |
| 2021 | ASCENDIS PHARMA A/S : Notice to convene Extraordinary General Meeting - Form 6-K | PU |
| 2021 | ASCENDIS PHARMA A/S : BofA Securities Downgrades Ascendis Pharma to Neutral From Buy, Lift.. | MT |
| 2021 | ASCENDIS PHARMA A/S : Wedbush Lifts Price Target for Ascendis Pharma A/S to $191 From $187.. | MT |
| 2021 | Certain Ordinary Shares of Ascendis Pharma A/S are subject to a Lock-Up Agreement Endin.. | CI |
| 2021 | Certain Warrants of Ascendis Pharma A/S are subject to a Lock-Up Agreement Ending on 1.. | CI |
| 2021 | U.S. Supreme Court refuses stay request for Spire Missouri natgas pipe | RE |
| 2021 | Health Care Stocks Climb Pre-Bell Friday | MT |
| 2021 | ASCENDIS PHARMA A/S : Health Care | MT |
| 2021 | ASCENDIS PHARMA A/S : INCORPORATION BY REFERENCE - Form 6-K | PU |
| 2021 | ASCENDIS PHARMA A/S : Begins US Commercial Launch of Pediatric Growth Hormone Deficiency T.. | MT |
| 2021 | ASCENDIS PHARMA A/S : Announces U.S. Commercial Launch of SKYTROFA® (Lonapegsomatropin-tcg.. | AQ |
| 2021 | Ascendis Pharma A/S Announces U.S. Commercial Launch of Skytrofa the First and Only FDA.. | CI |
| 2021 | European ADRs Move Lower in Wednesday Trading | MT |
| 2021 | ASCENDIS PHARMA A/S : Articles of Association (Form 6-K) | PU |
| 2021 | ASCENDIS PHARMA A/S : A/S Announces Presentations for TransCon™ PTH and TransCon&tra.. | GL |
| 2021 | Ascendis Pharma A/S Announces Presentations for TransCon PTH and TransCon CNP at the Am.. | CI |
| 2021 | ASCENDIS PHARMA A/S : to Buy Back Up to $25 Million in American Depositary Shares by Year-.. | MT |
| 2021 | ASCENDIS PHARMA A/S : Announces Share Repurchase Program | AQ |
| 2021 | Ascendis Pharma A/S announces an Equity Buyback for 300,000 shares, for $25 million. | CI |
| 2021 | Ascendis Pharma A/S authorizes a Buyback Plan. | CI |
| 2021 | PRIME MINING : Appoints New Board Member and Exploration Executive, Provides Update | MT |
| 2021 | European ADRs Move Sharply Higher in Thursday Trading | MT |
| 2021 | ASCENDIS PHARMA A/S : INCORPORATION BY REFERENCE (Form 6-K) | PU |
| 2021 | Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Fo.. | GL |
| 2021 | Ascendis Pharma A/S Announces Mean Bone Mineral Density Data from Phase 2 PaTH Forward .. | CI |
| 2021 | ASCENDIS PHARMA A/S : Articles of Association (Form 6-K) | PU |
| 2021 | ASCENDIS PHARMA A/S : Seeks FDA Nod to Start TransCon Trial in Patients with Advanced Canc.. | MT |
| 2021 | Ascendis Pharma A/S Announces Upcoming Investor Presentations | GL |
| 2021 | Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon&t.. | GL |
| 2021 | Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ .. | CI |
| 2021 | European ADRs Move Lower in Tuesday Trading | MT |
| 2021 | European ADRs Move Higher in Thursday Trading | MT |
| 2021 | ASCENDIS PHARMA A/S : Prices Offering at $160 Per ADS | MT |
| 2021 | Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs | GL |
| 2021 | Health Care Stocks Reverse Losses as Biotechs Rise | MT |
| 2021 | ADRs End Mostly Higher, Ascendis Pharma Trades Actively | DJ |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
